| Location
Guangzhou
| Position responsibilities and duties
- /
- //ELISA
- BBB/
- pipeline
- RTPCRVH/VL
- /owner
- B
- /SOPQCB
- /HypercellB/
- Lead the design and execution of innovative antibody discovery projects, covering the full workflow from immunization to candidate selection.
- Drive antibody discovery using conventional approaches, including: design and optimization of animal immunization strategies (e.g., mouse), hybridoma generation/screening/cloning, and antibody functional screening (ELISA, cell-based assays, etc.).
- Establish and implement next-generation single B cell-based antibody discovery workflows, including single B cell sorting (e.g., microfluidics or high-throughput systems), sample preparation (splenocyte preparation, plasma B cell enrichment, etc.), single-cell screening/recovery, and downstream workflow integration.
- Build and optimize high-throughput antibody discovery pipelines to improve efficiency, hit rate, and diversity, with a focus on robustness and reproducibility.
- Support antibody sequence generation and analysis, including single-cell RT-PCR, VH/VL amplification and sequencing, and utilizing bioinformatic tools for candidate selection and hit list generation.
- Act as a technical lead or project owner, mentoring junior scientists and driving team capability building.
- Evaluate and integrate emerging technologies (e.g., single B cell vs hybridoma strategies) and help define antibody discovery strategies for key project milestones.
- (Senior scope) Develop, document, and maintain SOPs and QC checkpoints across immunization, hybridoma, and single B cell workflows; deliver traceable records, data packages, and technical summaries.
- (Senior scope) Support platform operational readiness (training, key consumables planning, and vendor/equipment interfacing) to ensure stable throughput and data consistency for high-throughput single-cell screening platforms (e.g., Hypercell or similar systems).
- Perform other duties as assigned, in alignment with project and business needs.
/Qualifications:
| Education
- PhD. preferred/required in Immunology, Biology, Pharmacy, or related field (Masters with extensive experience may be considered).
| Experience
- Scientist 3 6-8/
- Senior Scientist 6 9/
- Scientist: Ph.D. with 3 years (or M.S. with 6-8 years) of relevant antibody discovery experience.
- Senior Scientist: Ph.D. with 6 years (or M.S. with 9 years) of relevant antibody discovery and/or platform development experience.
- Exceptional candidates may be considered with flexibility on years of experience (based on project depth and deliverables).
| Technical Skills
| Required
- /ELISA
- Strong hands-on experience in antibody discovery, including animal immunization strategy design/execution and hybridoma-based antibody generation/screening.
- Deep understanding of antibody screening and functional assays: ELISA, flow cytometry, and cell-based assays.
| Preferred
- B/FACSVH/VL
- Hypercell
- NGS/
- Experience with single B-cell antibody discovery: single-cell sorting (microfluidics/FACS) and VH/VL sequencing from single cells.
- Experience with high-throughput antibody discovery platforms (e.g., Hypercell or similar systems) and related workflows.
- Additional strengths: NGS data analysis, antibody engineering (humanization, affinity maturation), and bispecific/multispecific antibodies.
| Core Competencies
- owner
- Strong experimental design and problem-solving skills; ability to independently lead projects as a technical owner; team leadership and cross-functional collaboration; proficiency in English communication (oral and written).
Note: the final job title will be commensurate with the candidates seniority, skills and level of experience.
About Angitia
Established in June 2018, Angitia Biopharmaceuticals is a multinational research and development enterprise focusing on discovery and development of new drugs for grievous bone, muscle, and joint diseases. Our mission is to discover, develop and commercialize breakthrough therapeutics that address the key unmet medical needs of serious musculoskeletal diseases. The founder and the core team members of Angitia are seasoned scientific leaders in new drug discovery, development, and management from both overseas and domestic large multinational companies. The company has built an organization distinguished by world-class scientists with talents that are proficient in the pathophysiology of musculoskeletal diseases. We utilize cutting-edge technologies of genetics and molecular biology to uncover new mechanisms, signal transduction pathways and their interactions combined with computer aided drug design to identify new drug targets, and to discover and develop new biological and small molecule medicines. The company is committed to serving patients in need by carrying out innovative science including internal research and external collaborations with academics and global biopharmaceutical companies. We are seeking talent who are innovative, ambitious, and great team players to join our vibrant group.